RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on December 9th, 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety...
VBL Therapeutics announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer.